Advertisement
Screener

Novo Holdings A/S Historic Quarter Change: USA Other Stocks, Added

Novo Holdings A/S historic quarter change: USA Other Stocks, Added

In shares no fund filing gives a ticker for, so this site has no page for them (listed in the US), over 37 quarters from 2009-12-31 to 2026-06-30, Novo Holdings A/S opened 25 positions, added to 25, reduced 23 and sold out of 25.

  • Q2 2025: Stock BLUEPRINT MEDICINES CORP; Country of operation United States; Class COM; Shares before 228,804.
  • Q1 2025: Stock BLUEPRINT MEDICINES CORP; Country of operation United States; Class COM; Shares before 175,000.
  • Q1 2025: Stock VERVE THERAPEUTICS INC; Country of operation United States; Class COM; Shares before 2,400,000.
  • Q4 2024: Stock CARGO THERAPEUTICS INC; Country of operation United States; Class COM; Shares before 1,544,000.

Each consecutive pair of Form 13F-HR filings compared (SEC CIK 1388325), 37 quarters: Q2 2026 (2026-03-31 to 2026-06-30, filed 2026-08-14); Q1 2026 (2025-12-31 to 2026-03-31, filed 2026-05-15); Q4 2025 (2025-09-30 to 2025-12-31, filed 2026-02-17); Q3 2025 (2025-06-30 to 2025-09-30, filed 2025-11-14); Q2 2025 (2025-03-31 to 2025-06-30, filed 2025-08-14); Q1 2025 (2024-12-31 to 2025-03-31, filed 2025-05-15); Q4 2024 (2024-09-30 to 2024-12-31, filed 2025-02-14); Q3 2024 (2024-06-30 to 2024-09-30, filed 2024-10-24); Q2 2024 (2024-03-31 to 2024-06-30, filed 2024-08-20); Q1 2024 (2023-12-31 to 2024-03-31, filed 2024-05-15); Q3 2016 (2016-06-30 to 2016-09-30, filed 2016-11-14); Q2 2016 (2016-03-31 to 2016-06-30, filed 2016-08-15); Q1 2016 (2015-12-31 to 2016-03-31, filed 2016-05-16); Q4 2015 (2015-09-30 to 2015-12-31, filed 2016-02-16); Q3 2015 (2015-06-30 to 2015-09-30, filed 2015-11-16); Q2 2015 (2015-03-31 to 2015-06-30, filed 2015-08-14); Q1 2015 (2014-12-31 to 2015-03-31, filed 2015-05-15); Q4 2014 (2014-09-30 to 2014-12-31, filed 2015-02-17); Q3 2014 (2014-06-30 to 2014-09-30, filed 2014-11-14); Q2 2014 (2014-03-31 to 2014-06-30, filed 2014-08-14); Q1 2014 (2013-12-31 to 2014-03-31, filed 2014-08-14); Q4 2013 (2013-09-30 to 2013-12-31, filed 2014-08-14); Q3 2013 (2013-06-30 to 2013-09-30, filed 2014-11-14); Q2 2013 (2013-03-31 to 2013-06-30, filed 2014-11-14); Q1 2013 (2012-12-31 to 2013-03-31, filed 2014-11-14); Q4 2012 (2012-09-30 to 2012-12-31, filed 2014-11-14); Q3 2012 (2012-06-30 to 2012-09-30, filed 2014-11-14); Q2 2012 (2012-03-31 to 2012-06-30, filed 2014-11-14); Q1 2012 (2011-12-31 to 2012-03-31, filed 2014-11-14); Q4 2011 (2011-09-30 to 2011-12-31, filed 2014-11-14); Q3 2011 (2011-06-30 to 2011-09-30, filed 2014-11-14); Q2 2011 (2011-03-31 to 2011-06-30, filed 2014-11-14); Q1 2011 (2010-12-31 to 2011-03-31, filed 2014-11-14); Q4 2010 (2010-09-30 to 2010-12-31, filed 2014-11-14); Q3 2010 (2010-06-30 to 2010-09-30, filed 2014-11-14); Q2 2010 (2010-03-31 to 2010-06-30, filed 2014-11-14); Q1 2010 (2009-12-31 to 2010-03-31, filed 2014-11-14). Rows for the same security, class and put/call are added together. Value change is the filed value at each quarter end, so it includes the price move. Only the filings held here are compared; the firm's 13F-HR filings go back to the quarter ended 2013-12-31. Not compared, as a quarter between them is not held here yet: 2016-09-30 to 2023-12-31 (missing 2016-12-31, 2017-03-31, 2017-06-30, 2017-09-30, 2017-12-31, 2018-03-31, 2018-06-30, 2018-09-30, 2018-12-31, 2019-03-31, 2019-06-30, 2019-09-30, 2019-12-31, 2020-03-31, 2020-06-30, 2020-09-30, 2020-12-31, 2021-03-31, 2021-06-30, 2021-09-30, 2021-12-31, 2022-03-31, 2022-06-30, 2022-09-30, 2022-12-31, 2023-03-31, 2023-06-30, 2023-09-30).

QuarterStockCountry of operationClassShares beforeShares afterShare changeValue beforeValue afterValue changeFiled
Q2 2025BLUEPRINT MEDICINES CORP
CUSIP 09627Y109
United StatesCOM228,804264,956+36,152$20,251,442$33,962,060+$13,710,6182025-08-14
Q1 2025BLUEPRINT MEDICINES CORP
CUSIP 09627Y109
United StatesCOM175,000228,804+53,804$15,263,500$20,251,442+$4,987,9422025-05-15
Q1 2025VERVE THERAPEUTICS INC
CUSIP 92539P101
United StatesCOM2,400,0003,000,000+600,000$13,536,000$13,710,000+$174,0002025-05-15
Q4 2024CARGO THERAPEUTICS INC
CUSIP 14179K101
United StatesCOM1,544,0001,663,724+119,724$28,486,800$23,990,900-$4,495,9002025-02-14
Q2 2024VERVE THERAPEUTICS INC
CUSIP 92539P101
United StatesCOM2,000,0002,400,000+400,000$26,560,000$11,712,000-$14,848,0002024-08-20
Q2 2024CARGO THERAPEUTICS INC
CUSIP 14179K101
United StatesCOM1,250,0001,544,000+294,000$27,900,000$25,352,480-$2,547,5202024-08-20
Q3 2016COLUCID PHARMACEUTICALS INC
CUSIP 19716T101
COM3,056,5633,156,563+100,000$24,972,000$120,423,000+$95,451,0002016-11-14
Q3 2016ACCELERON PHARMA INC
CUSIP 00434H108
COM685,863903,833+217,970$23,306,000$32,710,000+$9,404,0002016-11-14
Q3 2016SPECTRANETICS CORP
CUSIP 84760C107
COM1,117,0021,155,722+38,720$20,899,000$28,997,000+$8,098,0002016-11-14
Q3 2016INVUITY INC
CUSIP 46187J205
COM1,075,4481,285,448+210,000$10,249,000$17,636,000+$7,387,0002016-11-14
Q3 2016FLEXION THERAPEUTICS INC
CUSIP 33938J106
COM950,1611,097,718+147,557$14,224,000$21,449,000+$7,225,0002016-11-14
Q3 2016NABRIVA THERAPEUTICS AG
CUSIP 62957M104
COM1,054,8231,116,660+61,837$7,911,000$7,872,000-$39,0002016-11-14
Q2 2016SPECTRANETICS CORP
CUSIP 84760C107
COM236,8261,117,002+880,176$3,439,000$20,899,000+$17,460,0002016-08-15
Q2 2016ACCELERON PHARMA INC
CUSIP 00434H108
COM673,063685,863+12,800$17,762,000$23,306,000+$5,544,0002016-08-15
Q2 2016INVUITY INC
CUSIP 46187J205
COM936,1931,075,448+139,255$6,759,000$10,249,000+$3,490,0002016-08-15
Q2 2016NABRIVA THERAPEUTICS AG
CUSIP 62957M104
COM874,9851,054,823+179,838$7,840,000$7,911,000+$71,0002016-08-15
Q1 2016INVUITY INC
CUSIP 46187J205
COM925,000936,193+11,193$8,158,000$6,759,000-$1,399,0002016-05-16
Q4 2015NABRIVA THERAPEUTICS AG
CUSIP 62957M104
COM867,127874,985+7,858$8,238,000$8,417,000+$179,0002016-02-16
Q3 2015INVUITY INC
CUSIP 46187J106
COM740,616787,282+46,666$10,457,000$11,038,000+$581,0002015-11-16
Q2 2015TOKAI PHARMACEUTICALS INC
CUSIP 88907J107
COM1,184,1961,238,252+54,056$13,381,000$16,469,000+$3,088,0002015-08-14
Q1 2015TOKAI PHARMACEUTICALS INC
CUSIP 88907J107
COM1,178,9921,184,196+5,204$17,378,000$13,381,000-$3,997,0002015-05-15
Q4 2014TETRAPHASE PHARMACEUTICALS INC
CUSIP 88165N105
COM900,0001,475,000+575,000$17,955,000$58,572,000+$40,617,0002015-02-17
Q4 2014FLEXION THERAPEUTICS INC
CUSIP 33938J106
COM1,783,1312,283,131+500,000$32,560,000$46,096,000+$13,536,0002015-02-17
Q4 2014TOKAI PHARMACEUTICALS INC
CUSIP 88907J107
COM1,075,0371,178,992+103,955$15,519,000$17,378,000+$1,859,0002015-02-17
Q3 2010BIOMIMETIC THERAPEUTICS INC
CUSIP 09064X101
COM3,720,0654,720,065+1,000,000$41,367,000$53,809,000+$12,442,0002014-11-14

Similar Firms

Firm NameCountry13F ValueHoldings
TRAPHAGEN INVESTMENT ADVISORS LLCUnited States$1.234B207
Greylock XIV GP LLCUnited States$1.235B1
MANGROVE PARTNERS IM, LLCUnited States$1.236B427
CAMPBELL NEWMAN ASSET MANAGEMENT INCUnited States$1.233B103
First Long Island Investors, LLCUnited States$1.232B70
CULLINAN ASSOCIATES INCUnited States$1.236B207
Magnus Financial Group LLCUnited States$1.232B373
WEATHERLY ASSET MANAGEMENT L. P.United States$1.236B186
Ikarian Capital, LLCUnited States$1.232B161
Washington Trust Advisors, Inc.United States$1.237B870